SEC Comment Letter 0000000000-23-009014 to Ernexa Therapeutics Inc. (ERNA)
Ernexa Therapeutics Inc.
Date: Aug. 17, 2023 · CIK: 0000748592 · Accession: 0000000000-23-009014
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273977
Letter
United States securities and exchange commission logo August 17, 2023 Matthew Angel, Ph.D. Chief Executive Officer and President Eterna Therapeutics Inc. 1035 Cambridge Street, Suite 18A Cambridge, MA 02141 Re:Eterna Therapeutics Inc. Registration Statement on Form S-3 Filed August 14, 2023 File No. 333-273977 Dear Matthew Angel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Win Rutherfurd, Esq.
Show Raw Text
United States securities and exchange commission logo
August 17, 2023
Matthew Angel, Ph.D.
Chief Executive Officer and President
Eterna Therapeutics Inc.
1035 Cambridge Street, Suite 18A
Cambridge, MA 02141
Re:Eterna Therapeutics Inc.
Registration Statement on Form S-3
Filed August 14, 2023
File No. 333-273977
Dear Matthew Angel:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Win Rutherfurd, Esq.